AxoGen Stock Forecast, Price & News

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

Is AxoGen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AxoGen stock.
View analyst ratings for AxoGen or view top-rated stocks.

How has AxoGen's stock been impacted by Coronavirus?

AxoGen's stock was trading at $10.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXGN stock has decreased by 10.4% and is now trading at $9.59.
View which stocks have been most impacted by COVID-19.

Are investors shorting AxoGen?

AxoGen saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 499,200 shares, a drop of 44.0% from the October 31st total of 890,800 shares. Based on an average daily trading volume, of 191,000 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.3% of the shares of the stock are short sold.
View AxoGen's Short Interest.

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Monday, February 28th 2022.
View our earnings forecast for AxoGen.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings data on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.05. The medical equipment provider had revenue of $31.20 million for the quarter, compared to the consensus estimate of $34.65 million. AxoGen had a negative net margin of 21.59% and a negative trailing twelve-month return on equity of 21.68%. During the same period in the prior year, the firm earned ($0.04) earnings per share.
View AxoGen's earnings history.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $127 million-$129 million, compared to the consensus revenue estimate of $135.29 million.

What price target have analysts set for AXGN?

4 analysts have issued 1 year target prices for AxoGen's stock. Their forecasts range from $20.00 to $27.00. On average, they expect AxoGen's share price to reach $23.50 in the next twelve months. This suggests a possible upside of 145.0% from the stock's current price.
View analysts' price targets for AxoGen or view top-rated stocks among Wall Street analysts.

Who are AxoGen's key executives?

AxoGen's management team includes the following people:

• Karen L. Zaderej, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• Mike Donovan, Vice President-Operations
• Peter J. Mariani, Chief Financial Officer & Executive Vice President
• Erick Wayne DeVinney, Vice President-Clinical & Translational Sciences
• Ivica Ducic, Medical Director

What is Karen Zaderej's approval rating as AxoGen's CEO?

3 employees have rated AxoGen CEO Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among AxoGen's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AxoGen's key competitors?

Some companies that are related to AxoGen include ViewRay (VRAY), Natus Medical (NTUS), Cutera (CUTR), Semler Scientific (SMLR), TransMedics Group (TMDX), Zynex (ZYXI), Stereotaxis (STXS), Edap Tms (EDAP), Movano (MOVE), FONAR (FONR), BioSig Technologies (BSGM), IRIDEX (IRIX), Electromed (ELMD), Second Sight Medical Products (EYES) and electroCore (ECOR).
View all of AXGN's competitors.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by many different retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (13.20%), BlackRock Inc. (7.07%), Janus Henderson Group PLC (3.14%), William Blair Investment Management LLC (2.93%), Baillie Gifford & Co. (2.81%) and Point72 Asset Management L.P. (2.71%). Company insiders that own AxoGen stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends for AxoGen.

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Balyasny Asset Management LLC, Assenagon Asset Management S.A., Point72 Asset Management L.P., Millennium Management LLC, Two Sigma Advisers LP, Parkman Healthcare Partners LLC, and Dimensional Fund Advisors LP. Company insiders that have sold AxoGen company stock in the last year include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, and Peter J Mariani.
View insider buying and selling activity for AxoGen or view top insider-selling stocks.

Which major investors are buying AxoGen stock?

AXGN stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, American Century Companies Inc., Citadel Advisors LLC, Crestline Management LP, Rice Hall James & Associates LLC, Bamco Inc. NY, BlackRock Inc., and Exchange Traded Concepts LLC.
View insider buying and selling activity for AxoGen or or view top insider-buying stocks.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $9.59.

How much money does AxoGen make?

AxoGen has a market capitalization of $398.59 million and generates $112.30 million in revenue each year. The medical equipment provider earns $-23.79 million in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does AxoGen have?

AxoGen employs 357 workers across the globe.

What is AxoGen's official website?

The official website for AxoGen is www.axogeninc.com.

Where are AxoGen's headquarters?

AxoGen is headquartered at 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at (386) 462-6800, via email at [email protected], or via fax at 386-462-6801.